LOGAN-CV: A Prospective Study of a Multifaceted Intervention Targeting United States Clinicians to Improve Guideline-Based Management of Lipid-Lowering Therapy.
J Nikki McKoyBethany A KalichLaura GreeneRachel H MackeyNing A RosenthalYosef KhanCezary WójcikJenna JonesLeslie A CarabuenaPublished in: Advances in therapy (2023)
The change in proportion of patients with LDL-C < 70 mg/dl achieved at any time during the 12-month intervention (primary); LLT intensification, changes in guideline-aligned LDL-C testing and LLT titration over 12 months, and change in overall clinicians' knowledge, attitudes, and beliefs are key outcomes of interest. The LOGAN-CV study addresses a critical unmet need in LDL-C control in patients with VHR ASCVD and evaluates the effect of a multifaceted intervention targeting clinicians to improve their adherence to guidelines and consequently improve clinical outcomes for patients.
Keyphrases
- randomized controlled trial
- palliative care
- end stage renal disease
- ejection fraction
- newly diagnosed
- cancer therapy
- healthcare
- peritoneal dialysis
- low density lipoprotein
- prognostic factors
- type diabetes
- drug delivery
- clinical practice
- metabolic syndrome
- mesenchymal stem cells
- skeletal muscle
- bone marrow
- insulin resistance
- fatty acid